I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.
August 18, 2017
Where is the sustainable value in cell therapy land again?
Share pricing leadership has its issues … it slips, dips and uncertainty keeps it uncontrollable
Preview RMi's morning call. To get the pre-open briefing, plus daily access of the happenings and realities of “our” universe - SUBSCRIBE!
June 1, 2017
Calling out the recent 10-Q page 17’s paragraph re a 24 page legal filing - this is what BSTG did NOT want investors to know or read!
August 18, 2017
As its outlook is murky, trends and patterns look opaque or just don’t exist
So, what is sector and market outlook?
… Continued pressure on share pricing!
Out and about; Biostage (BSTG) gets slammed again -$0.044 or -13.01% to a new bottom of $0.295 with 2.16 M shares traded. A far cry from Q1/15’s $4.43 and Q4/15’s $3.47 and Q1/16’s $2.60 and Q2’s $2.86 and Q4’s $1.42 … as January ‘17 started at $0.87 … great fiduciary performance – CEO McGorry!
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
June 27, 2017
On track for top-line 1 year powered data and potential BLA filing in Q3/18 BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019
June 26, 2017
BLUE closed down -$4.20 to $1.06.90 after Monday's -$0.90 or -0.80% to $111.10
June 20, 2017
SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 SGMO prices 10 M shares at $7.25
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
August 18, 2017
RegMed Investors’ (RMi) closing bell; short-term pullbacks are the theme of our sector
August 18, 2017
RegMed Investors’ (RMi) pre-open indications, markets has the jitters and the sector has the heebie-jeebies
August 17, 2017
RegMed Investors’ (RMi) closing bell; sector stumbles
August 17, 2017
RegMed Investors’ (RMi) pre-open indications, tensions heighten
August 16, 2017
RegMed Investors’ (RMi) closing bell; sector trips to a neutral location
August 16, 2017
RegMed Investors’ (RMi) pre-open indications, shuffling ahead with no clear direction
August 15, 2017
RegMed Investors’ (RMi) closing bell; flip, flop and fly down
August 15, 2017
RegMed Investors’ (RMi) pre-open indications, momentum or volatility
© 2017 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
